ICS Formulary
*Important*
The NENC ICB Respiratory Network recommends that all inhalers should be prescribed by brand for patient safety, to ensure that the correct device is dispensed to support correct technique and avoid patient confusion and medication errors.
Choice of inhaler device should be based on patient ability to use. Devices should be chosen based on availability for the type of drug to be prescribed and the patient’s ability to use it.
Refer to local guidelines for information on preferred options.
Note: All new patients should be started on the updated formulary choices as per local/national guidelines.
When inhalers are removed from the formulary, existing, stable, patients should continue to receive the non-formulary device. Treatment should not be changed unless a full face to face review has been conducted.
| Bee and Wasp Allergen Extracts Pharmalgen® |
|
Formulary
|
For use in adults and children by adult and paediatric immunologists only. Only approved for use in accordance with NICE guidance. |
 NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy |
|
| Grass and Tree Pollen Extract Pollinex® |
|
Formulary
|
For use in adults and children by adult and paediatric immunologists only. |
|
|
| House dust mite allergen immunotherapy Acarizax® |
|
Formulary
|
12 SQ-HDM SLIT oral lyophilisates
|
|
NICE TA1045: 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites |
|
|
| Peanut Allergy Palforzia® |
|
Formulary
|
Approved for the treatment of peanut allergy in children and young people in line with NICE
|
|
NICE TA769: Palforzia for treating peanut allergy in children and young people |
|
|
| Grass and Tree Pollen Extract Pollinex Quattro® |
|
Formulary
|
|
|
|
Links
- MHRA Drug Safety Update (July 2018): Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects
- MHRA Drug Safety Update Nov 2022: Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management
- MHRA: Adrenaline auto-injectors (AAIs): new guidance and resources for safe use
- NENC Adult Asthma Guideline
- NENC Asthma Prescribing Guidelines for Children and Young People 12 to 17 years
- NENC Asthma Prescribing Guidelines for Children and Young People 2 to 5 years
- NENC Asthma Prescribing Guidelines for Children and Young People 6-11 years
- NENC COPD Guideline
- NENC Management of COPD Exacerbations – Rescue medication in primary care
- NICE NG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
- NICE NG244: Asthma pathway (BTS, NICE, SIGN)
- NICE NG245: Asthma: diagnosis, monitoring and chronic asthma management
- NICE TA1045: 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites
- NICE TA1096: Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis
- NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy
- NICE TA278: Omalizumab for treating allergic asthma
- NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
- NICE TA479 Reslizumab for treating severe eosinophilic asthma
- NICE TA565: Benralizumab for treating severe eosinophilic asthma
- NICE TA671: Mepolizumab for treating severe eosinophilic asthma
- NICE TA678: Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)
- NICE TA751: Dupilumab for treating severe asthma with type 2 inflammation
- NICE TA769: Palforzia for treating peanut allergy in children and young people
- NICE TA880: Tezepelumab for treating severe asthma